Bioactive peptides derived from uteroglobin

Annals of the New York Academy of Sciences

Volumn 923, Issue , 2000, Pages 128-140

  Miele, Lucio ^a  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; ANTIFLAMMIN; LIPOCORTIN; OLIGOPEPTIDE; THROMBIN; UTEROGLOBIN; ANTIFLAMMIN P1; ANTIFLAMMIN P2; DRUG DERIVATIVE; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; CLARA CELL; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACTIVITY; HORMONAL REGULATION; HORMONE RELEASE; IN VIVO STUDY; LEUKOCYTE MIGRATION INHIBITION TEST; NONHUMAN; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; ANIMAL; DISEASE MODEL; HUMAN; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE; REVIEW;

ANIMALIA;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, SECONDARY; UTEROGLOBIN;

EID: 0034567899     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb05524.x     Document Type: Conference Paper

References (91)

1. Uteroglobin and uteroglobin-like proteins: The uteroglobin family of proteins
2. Uteroglobin: A novel cytokine?
3. Inhibition of thrombin-induced platelet aggregation by uteroglobin
4. Adherence and regulation of leukotaxis
5. Inhibition of phagocyte chemotaxis by uteroglobin, an inhibitor of blastocyst rejection
6. Novel anti-inflammatory peptides from the region of highest similarity between uteroglobin and lipocortin I
7. Recombinant human uteroglobin inhibits the in vitro invasiveness of human metastatic prostate tumor cells and the release of arachidonic acid stimulated by fibroblast-conditioned medium
8. Recombinant human uteroglobin suppresses cellular invasiveness via a novel class of high-affinity cell surface binding site
9. Uteroglobin (UG) suppresses extracellular matrix invasion by normal and cancer cells that express the high affinity UG-binding proteins
10. Overexpression of CC10 modifies neoplastic potential in lung cancer cells
11. Loss of transformed phenotype in cancer cells by overexpression of the uteroglobin gene
12. Severe fibronectin-deposit renal glomerular disease in mice lacking uteroglobin
13. Uteroglobin: Physiological role in normal glomerular function uncovered by targeted disruption of the uteroglobin gene in mice
14. Uteroglobin is essential in preventing immunoglobulin A nephropathy in mice
15. Normal function and lack of fibronectin accumulation in kidneys of Clara cell secretory protein/uteroglobin deficient mice
16. Binding of progesterone to the proteins of the uterine luminal fluid: Identification of uteroglobin as the binding protein
17. Binding of steroids to uteroglobin
18. Specific interaction of some non-steroidal compounds with the progesterone binding site of uteroglobin
19. The binding of methylsulfonyl-polychloro-biphenyls to uteroglobin
20. Purification and level of expression in bronchoalveolar lavage of a human polychlorinated biphenyl (PCB)-binding protein: Evidence for a structural and functional kinship to the multihormonally regulated protein uteroglobin
21. Binding of retinoids to uteroglobin
22. Uteroglobin inhibits phospholipase A2 activity
23. Modulation of cellular response to antigens by uteroglobin and transglutaminase
24. Inhibition of phospholipase A2 by uteroglobin and antiflammin peptides
25. Inhibition of pancreatic phospholipase A2 activity by uteroglobin and antiflammin peptides: Possible mechanism of action
26. Regulation of extracellular phospholipase A2 activity: Implications for inflammatory diseases
27. Calcium-dependent binding of uteroglobin (PCB-BP/CCSP) to negatively charged phospholipid liposomes
28. Binding of uteroglobin to microsomes and plasmatic membranes
29. Resonance assignment and secondary structure determination and stability of the recombinant human uteroglobin with heteronuclear multidimensional NMR
30. High level bacterial expression of uteroglobin, a dimeric eukaryotic protein with two interchain disulfide bridges, in its natural quaternary structure
31. Human Clara cell 10-kDa protein is the counterpart of rabbit uteroglobin
32. Stable, long-term bacterial production of soluble, dimeric, disulfide-bonded protein pharmaceuticals without antibiotic selection
33. Novel peptides derived from a region of local homology between uteroglobin and lipocortin-1 inhibit platelet aggregation and secretion
34. Anti-inflammatory peptides inhibit synthesis of platelet-activating factor
35. Antiflammins inhibit synthesis of platelet-activating factor and intradermal inflammatory reactions
36. Anti-inflammatory peptides (antiflammins) inhibit synthesis of platelet-activating factor, neutrophil aggregation and chemotaxis, and intradermal inflammatory reactions
37. Tumor necrosis factor alters cytoskeletal organization and barrier function of endothelial cells
38. Anti-inflammatory effects of vasocortin and nonapeptide fragments of uteroglobin and lipocortin I (antiflammins)
39. Selective inhibition of inflammatory reactions by vasocortin and antiflammin 2
40. Effects of antiflammins on endotoxin-induced uveitis in rats
41. A novel anti-inflammatory peptide from human lipocortin 5
42. Lipocortin-derived peptides
43. Suppression of interleukin-1 action by phospholipase-A2 inhibitors in helper T lymphocytes
44. In vitro and in vivo effects of the anti-inflammatory peptides, antiflammins
45. Antiflammins suppress the A23187- and arachidonic acid-dependent chloride secretion in rabbit distal colonic mucosa
46. Effect of nonapeptide fragments of uteroglobin and lipocortin I on oedema and mast cell degranulation
47. Antiflammins: Anti-inflammatory activity and effect on human phospholipase A2
48. Effects of an anti-inflammatory peptide (antiflammin 2) on cell influx, eicosanoid biosynthesis, and edema formation by arachidonic acid and tetradecanoyl phorbol dermal application
49. Antiflammin-2, a nonapeptide of lipocortin-1, inhibits leukocyte chemotaxis, but not arachidonic acid mobilization
50. Reduction of adhesion formation by intraperitoneal administration of anti-inflammatory peptide 2
51. Evidence that the substance P-induced enhancement of pacemaking in lymphatics of the guinea-pig mesentery occurs through endothelial release of thromboxane A2
52. Antiflammin 1 peptide delivered non-invasively by iontophoresis reduces irritant-induced inflammation in vivo
53. Suppressive effect of antiflammin-2 on compound 48/80-induced conjunctivitis: Role of phospholipase A2s and inducible nitric oxide synthase
54. Evidence that the ATP-induced increase in vasomotion of guinea-pig mesenteric lymphatics involves an endothelium-dependent release of thromboxane A2
55. The anti-inflammatory peptides, antiflammins, regulate the expression of adhesion molecules on human leukocytes and prevent neutrophil adhesion to endothelial cells
56. Annexins and phospholipase A2 inhibition
57. Inhibition of secreted phospholipases A2 by annexin V: Competition for anionic phospholipid interfaces allows an assessment of the relative interracial affinities of secreted phospholipases A2
58. Annexin-I inhibits phospholipase A2 by specific interaction, not by substrate depletion
59. Partial coverage of phospholipid model membranes with annexin V may completely inhibit their degradation by phospholipase A2
60. Inhibition of human cytosolic phospholipase A2 by human annexin V
61. 2+-binding site in the mechanism of inhibition
62. Refinement of the C222(1) crystal form of oxidized uteroglobin at 1.34 Å resolution
63. Design of immunomodulatory peptides based on active site structures
64. Structural basis for calcium binding by uteroglobins
65. Extracellular phospholipase A2 and histamine release from rat peritoneal mast cells
66. Interaction of synthetic peptides from annexin I and uteroglobin with lipid monolayers and their effect on phospholipase A2 activity
67. "Antiflammins": Two nonapeptide fragments of uteroglobin and lipocortin I have no phospholipase A2-inhibitory and anti-inflammatory activity
68. Antiflammin-2 (HDMNKVLDL) does not inhibit phospholipase A2 activities
69. Cloning and recombinant expression of a novel human low molecular weight Ca(2+)-dependent phospholipase A2
70. Bacterial expression and characterization of human pancreatic phospholipase A2
71. Bacterial expression and characterization of human secretory class V phospholipase A2
72. Platelet secretory phospholipase A2 fails to induce rabbit platelet activation and to release arachidonic acid in contrast with venom phospholipases A2
73. Inhibition of the synthesis of platelet-activating factor by anti-inflammatory peptides (antiflammins) without methionine
74. Degradation of antiflammin 2 in aqueous solution
75. Degradation of antiflammin 2 under acidic conditions
76. Oxidative degradation of antiflammin 2
77. Novel proliferative effect of phospholipase A2 in Swiss 3T3 cells via specific binding site
78. Characterization of a high affinity binding site for pancreatic-type phospholipase A2 in the rat: Its cellular and tissue distribution
79. Purification and characterization of a high-affinity binding protein for pancreatic-type phospholipase A2
80. Receptor-binding capability of pancreatic phospholipase A2 is separable from its enzymatic activity
81. Molecular cloning of pancreatic group I phospholipase A2 receptor
82. Multifunctional activity of the extracellular domain of the M-type (180 kDa) membrane receptor for secretory phospholipases A2
83. The human 180-kDa receptor for secretory phospholipases A2: Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization
84. Arachidonic acid release from NIH 3T3 cells by group-I phospholipase A2: Involvement of a receptor-mediated mechanism
85. Pancreatic-type phospholipase A2 activates prostaglandin E2 production in rat mesangial cells by receptor binding reaction
86. Evidence that porcine pancreatic phospholipase A2 via its high affinity receptor stimulates extracellular matrix invasion by normal and cancer cells
87. Contraction of guinea pig lung parenchyma by pancreatic type phospholipase A2 via its specific binding site
88. Pancreatic-type phospholipase A2 induces group II phospholipase A2 expression and prostaglandin biosynthesis in rat mesangial cells
89. Structural elements of secretory phospholipases A2 involved in the binding to M-type receptors
90. Binding and internalization of extracellular type-I phospholipase A2 in uterine stromal cells
91. Endocytic properties of the M-type 180-kDa receptor for secretory phospholipases A2